59781-10-1

Basic information

• Product Name: 2-Pyridinemethanol, 5-(phenylmethoxy)-, acetate (ester)
• CAS NO: 59781-10-1
• Molecular Formula: C15H15NO3
• Molecular Weight: 257.289
• Mol File: 59781-10-1.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 2-Pyridinemethanol, 5-(phenylmethoxy)-, acetate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinemethanol, 5-(phenylmethoxy)-, acetate (ester)(59781-10-1)
• EPA Substance Registry System: 2-Pyridinemethanol, 5-(phenylmethoxy)-, acetate (ester)(59781-10-1)

Safety Data

• Hazardous Substances Data: 59781-10-1(Hazardous Substances Data)

Upstream product

• 59781-09-8 5-(benzyloxy)-2-methylpyridine 1-oxide 
• 108-24-7 acetic anhydride 
• 100-39-0 benzyl bromide 
• 63793-98-6 5-benzyloxy-2-methyl-pyridine 
• 1121-78-4 5-Hydroxy-2-methylpyridine 

Downstream Products

• 648415-02-5 [1-(5-Benzyloxy-pyridin-2-yl)-meth-(E)-ylidene]-trimethylsilanyl-amine 
• 647840-12-8 (3R,4S)-4-(5-benzyloxy-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone 
• 647840-13-9 (3R,4S)-4-(5-benzyloxy-2-pyridyl)-1-(tert-butoxycarbonyl)-3-triisopropylsilyloxy-2-azetidinone 
• 647840-15-1 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-hydroxypropionate 
• 647840-16-2 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-(morpholino)ethylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-hydroxypropionate 
• 647840-14-0 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-triisopropylsilyloxypropionate 
• 1612163-89-9 (E)-2-(2-(5-(benzyloxy)pyridin-2-yl)vinyl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine 
• 262277-51-0 (S)-3-{[7-(3-Amino-propoxy)-4-oxo-4H-quinolizine-2-carbonyl]-amino}-2-benzenesulfonylamino-propionic Acid Trifluoroacetic Acid Salt 
• 262278-27-3 7-benzyloxy-4-oxo-4H-quinolizine-2-carboxylic acid methyl ester 
• 262278-34-2 (S)-2-benzenesulfonylamino-3-{[7-(3-tert-butoxycarbonylamino-propoxy)-4-oxo-4H-quinolizine-2-carbonyl]-amino}-propionic acid tert-butyl ester 
• 262278-59-1 (S)-2-Benzenesulfonylamino-3-({4-oxo-7-[3-(pyrimidin-2-ylamino)-propoxy]-4H-quinolizine-2-carbonyl)-amino)-propionic Acid tert-butyl Ester 
• 59781-08-7 5-benzyloxypyridin-2-carbaldehyde 
• 909913-44-6 (2S,3S)-1-acetoxy-3-[2-(5-benzyloxypyridyl)]-3-tert-butyldimethylsilyloxy-2-methyl-3-propanol 

Relevant articles and documents

Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation

Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe

OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE

The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.